Status:
COMPLETED
Effect of Denileukin Diftitox on Immune System in CTCL Patients
Lead Sponsor:
University of Pittsburgh
Conditions:
Cutaneous T-cell Lymphoma
Sezary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. ...
Detailed Description
Although the etiology of CTCL is not fully understood, it is believed to be a malignancy proliferation of a "memory" T-cell in the context of Th2-type cytokine profile and suppressed cytotoxic T-cell ...
Eligibility Criteria
Inclusion
- 18 and older
- diagnosed with CTCL
- able and willing to provide informed consent
- will be receiving denileukin diftitox per standard guidelines
Exclusion
- prior history of receiving Ontak
- pregnancy
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00254332
Start Date
November 1 2005
End Date
September 1 2007
Last Update
March 25 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsubrgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213